Trial Profile

A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients With NNS/CANDLE, SAVI, and AGS

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 21 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baricitinib (Primary)
Indications Aicardi-Goutieres syndrome; Hereditary autoinflammatory diseases
Focus Registrational; Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

13 Feb 2025 Status changed from active, no longer recruiting to discontinued. (Reason the study was stopped: The study was terminated due to efficacy/effectiveness reasons)
24 Jul 2024 Planned End Date changed from 30 Apr 2025 to 1 Nov 2024.
17 Aug 2022 Planned End Date changed from 31 Oct 2023 to 30 Apr 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com